Evolution and development of drug therapy for triple negative breast neoplasms: an integrative review
DOI:
https://doi.org/10.33448/rsd-v12i3.40413Keywords:
Triple negative breast neoplasms; Drug Therapy; Clinical trial.Abstract
This article aims to analyze and criticize the existing experiences of pharmacological therapy for the treatment of triple-negative breast cancer (TNBC), in order to understand the possibility of significant advances in the area. TNBC, in particular, generates an intense concern among health professionals, patients, and families due to the high frequency of unfavorable prognosis and its incidence in young patients. Thus, it was decided to carry out the integrative literature review model, using as a bibliographic framework the articles in the electronic databases: PUBMED (Publisher Medline) and VHL (Virtual Health Library). Therefore, those publications that correctly related the keywords and passed through the selection filters were chosen, that is, those that contained relevant information and were capable of substantially adding to the discussion. Then, data was collected about the performance of different drugs in the treatment of 6 different types of TNBC, including cyclophosphamide, taxanes, and platinum, among others. In addition, positive results were also found for the combination of different drugs, and the alliance with more traditional methods such as chemotherapy, establishing neoadjuvant chemotherapy. In addition to the improvement in survival rates resulting from experiments carried out with checkpoint inhibitor drugs and even the approval of some of these by federal health bodies, it is possible to infer that the existing pharmacological treatments denote an adequate result, but which represents, however, a minority portion of the great potential to be explored through the development of new therapeutic procedures with drugs already known to be effective, and with new ones that have yet to be tested.
References
Adel, N. G. (2021). Current treatment landscape and emerging therapies for metastatic triple-negative breast cancer. The American journal of managed care, 27(5), 87–96.
Aine, M., Boyaci, C., Hartman, J., Häkkinen, J., Mitra, S., Campos, A. B., & Staaf, J. (2021). Molecular analyses of triple-negative breast cancer in the young and elderly. Breast cancer research : BCR, 23(1), 20.
Al-Mahmood, S., Sapiezynski, J., Garbuzenko, O. B., & Minko, T. (2018). Metastatic and triple-negative breast cancer: challenges and treatment options. Drug Deliv Transl Res, 8(5), 1483-1507.
Baranova, A., Krasnoselskyi, M., Starikov, V., Kartashov, S., Zhulkevych, I., Vlasenko, V., & Vinnyk, Y. (2022). Triple-negative breast cancer: current treatment strategies and factors of negative prognosis. Journal of medicine and life, 15(2), 153–161.
Bergin, A. R. T., & Loi, S. (2019). Triple-negative breast cancer: recent treatment advances. F1000Research, 8, 1342.
Ferlay, J., Ervik, M., Lam, F., Colombet, M., Mery, L., Piñeros, M., & Bray, F. (2018). Global cancer observatory: cancer today. Lyon, France: international agency for research on cancer. https://gco.iarc. fr/today.
Ferrari, P., Scatena, C., Ghilli, M., Bargagna, I., Lorenzini, G., & Nicolini, A. (2022). Molecular Mechanisms, Biomarkers and Emerging Therapies for Chemotherapy Resistant TNBC. International journal of molecular sciences, 23(3), 1665.
Garrido-Castro, A. C., Lin, N. U., & Polyak, K. (2019). Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment. Cancer Discovery, 9(2), 176-198.
Giugliano, F., Valenza, C., Tarantino, P., & Curigliano, G. (2022). Immunotherapy for triple negative breast cancer: How can pathologic responses to experimental drugs in early-stage disease be enhanced? Expert Opin Investig Drugs, 31(8), 855-874.
Heeke, A. L., & Tan, A. R. (2021). Checkpoint inhibitor therapy for metastatic triple-negative breast cancer. Cancer and Metastasis Reviews, 40(2), 537-547.
Hwang, S., Park, S., & Kwon, Y. (2019). Recent therapeutic trends and promising targets in triple negative breast cancer. Pharmacol Ther, 199, 30-57.
Luo, L., & Keyomarsi, K. (2022). PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers. Expert Opin Investig Drugs, 31(6), 607-631.
Lyons, T. G. (2019). Targeted Therapies for Triple-Negative Breast Cancer. Current Treatment Options in Oncology, 20(11), 82.
Mendes, K. D. S., Silveira, R. C. C. P., & Galvão, C. M. (2019). Use Of The Bibliographic Reference Manager In The Selection Of Primary Studies In Integrative Reviews. Texto & Contexto - Enfermagem, 28, 1-13.
Mezni, E., Behi, K., & Gonçalves, A. (2022). Immunotherapy and breast cancer: an overview. Curr Opin Oncol, 34(5), 587-594.
Schlam, I., & Gatti-Mays, M. E. (2022). Immune Checkpoint Inhibitors in the Treatment of Breast Cancer Brain Metastases. The Oncologist, 27(7), 538-547.
So, J. Y., Ohm, J., Lipkowitz, S., & Yang, L. (2022). Triple negative breast cancer (TNBC): Non-genetic tumor heterogeneity and immune microenvironment: Emerging treatment options. Pharmacology & therapeutics, 237, 108253.
Sukumar, J., Gast, K., Quiroga, D., Lustberg, M., & Williams, N. (2021). Triple-negative breast cancer: promising prognostic biomarkers currently in development. Expert review of anticancer therapy, 21(2), 135-148.
Won, K., & Spruck, C. (2020). Triple‑negative breast cancer therapy: Current and future perspectives (Review). International Journal of Oncology, 57(6), 1245-1261.
Yin, L., Duan, J., Bian, X., & Yu, S. (2020). Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Research, 22(1), 61.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Maria Clara de Holanda Vieira Vasconcelos; Guilherme Couto Pimentel Lopes de Freitas; João Victor Araújo Diniz Loureiro; Vinícius Acioli da Cunha
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
